Evidence map›Paper›PMID 26354990›Full record

ArticleNeurology2015

Interictal, circulating sphingolipids in women with episodic migraine: A case-control study.

B Lee Peterlin, Michelle M Mielke, Alex M Dickens, Subroto Chatterjee, Paul Dash, Guillermo Alexander, Rebeca V A Vieira, Veera Venkata Ratnam Bandaru, Joelle M Dorskind, Gretchen E Tietjen and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. The role of dihydrosphingolipids in disease.Cellular and molecular life sciences : CMLS · 2019
    Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

B Lee PeterlinFrom the Department of Neurology (B.L.P., A.M.D., R.V.A.V., V.V.R.B., J.M.D., N.H.H.), Department of Pediatrics, Lipid Research Atherosclerosis Unit (S.C.), and Department of Psychiatry (N.H.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Health Sciences Research (M.M.M.), Division of Epidemiology, and Department of Neurology, Mayo Clinic, Rochester, MN; Department of Neurology (P.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Neurology (G.A.), Drexel University College of Medicine, Philadelphia, PA; Department of Psychology (R.V.A.V.), Federal University of Rio Grande do Sul, Porto Alegre, Brazil; and Department of Neurology (G.E.T.), University of Toledo, OH. lpeterlin@jhmi.edu.
Michelle M MielkeFrom the Department of Neurology (B.L.P., A.M.D., R.V.A.V., V.V.R.B., J.M.D., N.H.H.), Department of Pediatrics, Lipid Research Atherosclerosis Unit (S.C.), and Department of Psychiatry (N.H.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Health Sciences Research (M.M.M.), Division of Epidemiology, and Department of Neurology, Mayo Clinic, Rochester, MN; Department of Neurology (P.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Neurology (G.A.), Drexel University College of Medicine, Philadelphia, PA; Department of Psychology (R.V.A.V.), Federal University of Rio Grande do Sul, Porto Alegre, Brazil; and Department of Neurology (G.E.T.), University of Toledo, OH.
Alex M DickensFrom the Department of Neurology (B.L.P., A.M.D., R.V.A.V., V.V.R.B., J.M.D., N.H.H.), Department of Pediatrics, Lipid Research Atherosclerosis Unit (S.C.), and Department of Psychiatry (N.H.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Health Sciences Research (M.M.M.), Division of Epidemiology, and Department of Neurology, Mayo Clinic, Rochester, MN; Department of Neurology (P.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Neurology (G.A.), Drexel University College of Medicine, Philadelphia, PA; Department of Psychology (R.V.A.V.), Federal University of Rio Grande do Sul, Porto Alegre, Brazil; and Department of Neurology (G.E.T.), University of Toledo, OH.
Subroto ChatterjeeFrom the Department of Neurology (B.L.P., A.M.D., R.V.A.V., V.V.R.B., J.M.D., N.H.H.), Department of Pediatrics, Lipid Research Atherosclerosis Unit (S.C.), and Department of Psychiatry (N.H.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Health Sciences Research (M.M.M.), Division of Epidemiology, and Department of Neurology, Mayo Clinic, Rochester, MN; Department of Neurology (P.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Neurology (G.A.), Drexel University College of Medicine, Philadelphia, PA; Department of Psychology (R.V.A.V.), Federal University of Rio Grande do Sul, Porto Alegre, Brazil; and Department of Neurology (G.E.T.), University of Toledo, OH.
Paul DashFrom the Department of Neurology (B.L.P., A.M.D., R.V.A.V., V.V.R.B., J.M.D., N.H.H.), Department of Pediatrics, Lipid Research Atherosclerosis Unit (S.C.), and Department of Psychiatry (N.H.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Health Sciences Research (M.M.M.), Division of Epidemiology, and Department of Neurology, Mayo Clinic, Rochester, MN; Department of Neurology (P.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Neurology (G.A.), Drexel University College of Medicine, Philadelphia, PA; Department of Psychology (R.V.A.V.), Federal University of Rio Grande do Sul, Porto Alegre, Brazil; and Department of Neurology (G.E.T.), University of Toledo, OH.
Guillermo AlexanderFrom the Department of Neurology (B.L.P., A.M.D., R.V.A.V., V.V.R.B., J.M.D., N.H.H.), Department of Pediatrics, Lipid Research Atherosclerosis Unit (S.C.), and Department of Psychiatry (N.H.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Health Sciences Research (M.M.M.), Division of Epidemiology, and Department of Neurology, Mayo Clinic, Rochester, MN; Department of Neurology (P.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Neurology (G.A.), Drexel University College of Medicine, Philadelphia, PA; Department of Psychology (R.V.A.V.), Federal University of Rio Grande do Sul, Porto Alegre, Brazil; and Department of Neurology (G.E.T.), University of Toledo, OH.
Rebeca V A VieiraFrom the Department of Neurology (B.L.P., A.M.D., R.V.A.V., V.V.R.B., J.M.D., N.H.H.), Department of Pediatrics, Lipid Research Atherosclerosis Unit (S.C.), and Department of Psychiatry (N.H.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Health Sciences Research (M.M.M.), Division of Epidemiology, and Department of Neurology, Mayo Clinic, Rochester, MN; Department of Neurology (P.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Neurology (G.A.), Drexel University College of Medicine, Philadelphia, PA; Department of Psychology (R.V.A.V.), Federal University of Rio Grande do Sul, Porto Alegre, Brazil; and Department of Neurology (G.E.T.), University of Toledo, OH.
Veera Venkata Ratnam BandaruFrom the Department of Neurology (B.L.P., A.M.D., R.V.A.V., V.V.R.B., J.M.D., N.H.H.), Department of Pediatrics, Lipid Research Atherosclerosis Unit (S.C.), and Department of Psychiatry (N.H.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Health Sciences Research (M.M.M.), Division of Epidemiology, and Department of Neurology, Mayo Clinic, Rochester, MN; Department of Neurology (P.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Neurology (G.A.), Drexel University College of Medicine, Philadelphia, PA; Department of Psychology (R.V.A.V.), Federal University of Rio Grande do Sul, Porto Alegre, Brazil; and Department of Neurology (G.E.T.), University of Toledo, OH.
Joelle M DorskindFrom the Department of Neurology (B.L.P., A.M.D., R.V.A.V., V.V.R.B., J.M.D., N.H.H.), Department of Pediatrics, Lipid Research Atherosclerosis Unit (S.C.), and Department of Psychiatry (N.H.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Health Sciences Research (M.M.M.), Division of Epidemiology, and Department of Neurology, Mayo Clinic, Rochester, MN; Department of Neurology (P.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Neurology (G.A.), Drexel University College of Medicine, Philadelphia, PA; Department of Psychology (R.V.A.V.), Federal University of Rio Grande do Sul, Porto Alegre, Brazil; and Department of Neurology (G.E.T.), University of Toledo, OH.
Gretchen E TietjenFrom the Department of Neurology (B.L.P., A.M.D., R.V.A.V., V.V.R.B., J.M.D., N.H.H.), Department of Pediatrics, Lipid Research Atherosclerosis Unit (S.C.), and Department of Psychiatry (N.H.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Health Sciences Research (M.M.M.), Division of Epidemiology, and Department of Neurology, Mayo Clinic, Rochester, MN; Department of Neurology (P.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Neurology (G.A.), Drexel University College of Medicine, Philadelphia, PA; Department of Psychology (R.V.A.V.), Federal University of Rio Grande do Sul, Porto Alegre, Brazil; and Department of Neurology (G.E.T.), University of Toledo, OH.
Norman H HaugheyFrom the Department of Neurology (B.L.P., A.M.D., R.V.A.V., V.V.R.B., J.M.D., N.H.H.), Department of Pediatrics, Lipid Research Atherosclerosis Unit (S.C.), and Department of Psychiatry (N.H.H.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Health Sciences Research (M.M.M.), Division of Epidemiology, and Department of Neurology, Mayo Clinic, Rochester, MN; Department of Neurology (P.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Neurology (G.A.), Drexel University College of Medicine, Philadelphia, PA; Department of Psychology (R.V.A.V.), Federal University of Rio Grande do Sul, Porto Alegre, Brazil; and Department of Neurology (G.E.T.), University of Toledo, OH.
Mayo Clinic in Florida · USUniversity of Toledo · USUniversidade Federal do Rio Grande do Sul · BRDrexel University · US

Funding

Therapeutic CoreP30MH075673 · NIMH · JOHNS HOPKINS UNIVERSITY · PI Leah Helane Rubin · 2006 to 2026
$33.2M
Surrogate Marker CoreP01MH105280 · NIMH · JOHNS HOPKINS UNIVERSITY · PI SACKTOR, NED C · 2015 to 2019
$6.5M
Impact and Mechansims of Migraine Comorbidites on Migraine Onset and ProgressionK23NS078345 · NINDS · JOHNS HOPKINS UNIVERSITY · PI PETERLIN, BARBARA LEE · 2012 to 2016
$888k
NIMH NIH HHS P01 MH105280NINDS NIH HHS K23 NS078345NINDS NIH HHS K23-NS078345
6 · The paper itself

Abstract

objectiveTo evaluate interictal, circulating sphingolipids in women migraineurs.

methodsIn the fasting state, serum samples were obtained pain-free from 88 women with episodic migraine (EM; n=52) and from controls (n=36). Sphingolipids were detected and quantified by high-performance liquid chromatography coupled with tandem mass spectrometry using multiple reaction monitoring. Multivariate logistic regression was used to examine the association between serum sphingolipids and EM odds. A recursive partitioning decision tree based on the serum concentrations of 10 sphingolipids was used to determine the presence or absence of EM in a subset of participants.

resultsTotal ceramide (EM 6,502.9 ng/mL vs controls 10,518.5 ng/mL; p<0.0001) and dihydroceramide (EM 39.3 ng/mL vs controls 63.1 ng/mL; p<0.0001) levels were decreased in those with EM as compared with controls. Using multivariate logistic regression, each SD increase in total ceramide (odds ratio [OR] 0.07; 95% confidence interval [CI]: 0.02, 0.22; p<0.001) and total dihydroceramide (OR 0.05; 95% CI: 0.01, 0.21; p<0.001) levels was associated with more than 92% reduced odds of migraine. Although crude sphingomyelin levels were not different in EM compared with controls, after adjustments, every SD increase in the sphingomyelin species C18:0 (OR 4.28; 95% CI: 1.87, 9.81; p=0.001) and C18:1 (OR 2.93; 95% CI: 1.55, 5.54; p=0.001) was associated with an increased odds of migraine. Recursive portioning models correctly classified 14 of 14 randomly selected participants as EM or control.

conclusionThese results suggest that sphingolipid metabolism is altered in women with EM and that serum sphingolipid panels may have potential to differentiate EM presence or absence. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that serum sphingolipid panels accurately distinguish women with migraine from women without migraine.

Indexed as

AdolescentAdultCase-Control StudiesCeramidesDepressionFemaleHumansMiddle AgedMigraine DisordersOdds RatioSphingolipidsTandem Mass SpectrometryYoung AdultCeramidesdihydroceramideSphingolipids

Identifiers

PMID26354990
PMCPMC4607595
OpenAlexW1948310876

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.